In the ELDERCARE‐AF trial subanalysis, low‐dose edoxaban (15 mg) demonstrated consistent benefits in elderly atrial fibrillation patients, even with extremely low body weight (≤45 kg). The study included 984 Japanese patients considered ineligible for standard oral anticoagulants due to bleeding risk. Edoxaban reduced stroke or systemic embolism in both weight groups (≤45 kg: HR 0.36; >45 kg: HR 0.31) but showed a numerically higher incidence of major bleeding (≤45 kg: HR 3.05; >45 kg: HR 1.40). Clinicians are advised to monitor the risk of major bleeding, especially gastrointestinal bleeding, in this population.
Like
Save
Share